GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Biological: albiglutide
Drug: insulin glargine

First Posted Date: 2009-02-09

Last Posted Date: 2017-01-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 779

Registration Number: NCT00838916

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: placebo to match albiglutide
Biological: albiglutide
Drug: metformin
Drug: glimepiride
Drug: pioglitazone
Drug: placebo to match pioglitazone

First Posted Date: 2009-02-09

Last Posted Date: 2017-01-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 685

Registration Number: NCT00839527

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A

Phase 3

Completed

Conditions: Infections, Streptococcal
Streptococcus Pneumoniae

Interventions: Biological: GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)
Biological: GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)
Biological: Pneumococcal conjugate vaccine Synflorix (GSK1024850A)

First Posted Date: 2009-02-09

Last Posted Date: 2020-12-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6181

Registration Number: NCT00839254

Locations: 🇫🇮
GSK Investigational Site, Vantaa, Finland

BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder

Phase 3

Completed

Conditions: Post-Traumatic Stress Disorder

Interventions: Drug: Paroxetine

First Posted Date: 2009-02-09

Last Posted Date: 2014-03-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 52

Registration Number: NCT00839397

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Biological: albiglutide
Drug: sitagliptin
Drug: glimepiride
Drug: metformin
Drug: placebo sitagliptin
Biological: placebo albiglutide
Drug: placebo glimepiride

First Posted Date: 2009-02-09

Last Posted Date: 2017-01-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1049

Registration Number: NCT00838903

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

Phase 3

Completed

Conditions: Tetanus
Diphtheria
Acellular Pertussis
Diphtheria-Tetanus-acellular Pertussis Vaccines

Interventions: Biological: Boostrix®
Biological: Decavac™

First Posted Date: 2009-02-03

Last Posted Date: 2020-01-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1332

Registration Number: NCT00835237

Locations: 🇺🇸
GSK Investigational Site, Wenatchee, Washington, United States

Safety Escalating Repeat IV, in Stroke Patients

Phase 2

Completed

Conditions: Ischaemic Attack, Transient

Interventions: Drug: PLACEBO
Drug: GSK249320

First Posted Date: 2009-02-02

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 42

Registration Number: NCT00833989

Locations: 🇩🇪
GSK Investigational Site, Leipzig, Sachsen, Germany

Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: Eltrombopag and Lopinavir/Ritonavir
Drug: Lopinavir/Ritonavir
Drug: Eltrombopag

First Posted Date: 2009-02-02

Last Posted Date: 2017-11-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT00833378

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

GSK1349572 Mass Balance Study

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: [14c}-GSK1349572

First Posted Date: 2009-01-26

Last Posted Date: 2009-06-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6

Registration Number: NCT00828763

Locations: 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Phase 3

Completed

Conditions: Idiopathic Thrombocytopenic Purpura
Purpura, Thrombocytopenic, Idiopathic

Interventions: Drug: Eltrombopag oral tablets

First Posted Date: 2009-01-26

Last Posted Date: 2018-09-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 19

Registration Number: NCT00828750

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy